242 related articles for article (PubMed ID: 34238254)
1. Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA).
Hallal M; Braga-Lagache S; Jankovic J; Simillion C; Bruggmann R; Uldry AC; Allam R; Heller M; Bonadies N
BMC Cancer; 2021 Jul; 21(1):789. PubMed ID: 34238254
[TBL] [Abstract][Full Text] [Related]
2. Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines.
van Alphen C; Cloos J; Beekhof R; Cucchi DGJ; Piersma SR; Knol JC; Henneman AA; Pham TV; van Meerloo J; Ossenkoppele GJ; Verheul HMW; Janssen JJWM; Jimenez CR
Mol Cell Proteomics; 2020 May; 19(5):884-899. PubMed ID: 32102969
[TBL] [Abstract][Full Text] [Related]
3. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
6. Integrating phosphoproteomics into kinase-targeted cancer therapies in precision medicine.
Wu X; Xing X; Dowlut D; Zeng Y; Liu J; Liu X
J Proteomics; 2019 Jan; 191():68-79. PubMed ID: 29621648
[TBL] [Abstract][Full Text] [Related]
7. Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines.
Dayal N; Opoku-Temeng C; Hernandez DE; Sooreshjani MA; Carter-Cooper BA; Lapidus RG; Sintim HO
Future Med Chem; 2018 Apr; 10(7):823-835. PubMed ID: 29437468
[TBL] [Abstract][Full Text] [Related]
8. Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells.
Roolf C; Dybowski N; Sekora A; Mueller S; Knuebel G; Tebbe A; Murua Escobar H; Godl K; Junghanss C; Schaab C
Mol Cell Proteomics; 2017 Jul; 16(7):1365-1376. PubMed ID: 28450419
[TBL] [Abstract][Full Text] [Related]
9. Cytarabine-Resistant
Ko YC; Hu CY; Liu ZH; Tien HF; Ou DL; Chien HF; Lin LI
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30862120
[TBL] [Abstract][Full Text] [Related]
10. Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection.
Staudt DE; Murray HC; Skerrett-Byrne DA; Smith ND; Jamaluddin MFB; Kahl RGS; Duchatel RJ; Germon ZP; McLachlan T; Jackson ER; Findlay IJ; Kearney PS; Mannan A; McEwen HP; Douglas AM; Nixon B; Verrills NM; Dun MD
Clin Proteomics; 2022 Dec; 19(1):48. PubMed ID: 36536316
[TBL] [Abstract][Full Text] [Related]
11. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells.
Weisberg E; Ray A; Nelson E; Adamia S; Barrett R; Sattler M; Zhang C; Daley JF; Frank D; Fox E; Griffin JD
PLoS One; 2011; 6(9):e25351. PubMed ID: 21980431
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
[TBL] [Abstract][Full Text] [Related]
13. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
Gozgit JM; Wong MJ; Wardwell S; Tyner JW; Loriaux MM; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Druker BJ; Clackson T; Rivera VM
Mol Cancer Ther; 2011 Jun; 10(6):1028-35. PubMed ID: 21482694
[TBL] [Abstract][Full Text] [Related]
14. Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells.
Weber C; Schreiber TB; Daub H
J Proteomics; 2012 Feb; 75(4):1343-56. PubMed ID: 22115753
[TBL] [Abstract][Full Text] [Related]
15. The influence of delay in mononuclear cell isolation on acute myeloid leukemia phosphorylation profiles.
van Alphen C; Cucchi DGJ; Cloos J; Schelfhorst T; Henneman AA; Piersma SR; Pham TV; Knol JC; Jimenez CR; Janssen JJWM
J Proteomics; 2021 Apr; 238():104134. PubMed ID: 33561558
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD
Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863
[TBL] [Abstract][Full Text] [Related]
17. CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors.
Makishima H; Sugimoto Y; Szpurka H; Clemente MJ; Ng KP; Muramatsu H; O'Keefe C; Saunthararajah Y; Maciejewski JP
Leukemia; 2012 Jul; 26(7):1547-54. PubMed ID: 22246246
[TBL] [Abstract][Full Text] [Related]
18. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
19. Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance.
Alcolea MP; Casado P; Rodríguez-Prados JC; Vanhaesebroeck B; Cutillas PR
Mol Cell Proteomics; 2012 Aug; 11(8):453-66. PubMed ID: 22547687
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Grundy M; Seedhouse C; Russell NH; Pallis M
BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
